Neumora Therapeutics’ (NMRA) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a research report released on Tuesday,Benzinga reports. They currently have a $8.00 price objective on the stock.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. William Blair raised Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Leerink Partners initiated coverage on Neumora Therapeutics in a research report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price target for the company. Royal Bank Of Canada upgraded Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $4.00 to $7.00 in a research note on Monday, December 1st. Finally, Mizuho set a $6.00 price objective on Neumora Therapeutics in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.67.

Neumora Therapeutics Price Performance

Shares of NASDAQ:NMRA opened at $2.00 on Tuesday. The firm has a market capitalization of $364.08 million, a PE ratio of -1.38 and a beta of 3.08. The company has a quick ratio of 6.85, a current ratio of 6.85 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $2.74 and a two-hundred day moving average price of $2.32. Neumora Therapeutics has a twelve month low of $0.61 and a twelve month high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Equities analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current year.

Insider Transactions at Neumora Therapeutics

In other Neumora Therapeutics news, insider Paul L. Berns sold 9,819 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the sale, the insider directly owned 7,395,185 shares in the company, valued at $25,957,099.35. This represents a 0.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 23,387 shares of company stock valued at $82,647. Corporate insiders own 26.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. AlphaCore Capital LLC boosted its stake in Neumora Therapeutics by 89.1% during the third quarter. AlphaCore Capital LLC now owns 638,784 shares of the company’s stock valued at $1,163,000 after buying an additional 301,017 shares during the period. Vanguard Personalized Indexing Management LLC increased its stake in Neumora Therapeutics by 10.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock worth $117,000 after acquiring an additional 6,233 shares during the last quarter. Meridian Wealth Management LLC bought a new position in Neumora Therapeutics in the 3rd quarter worth about $108,000. Brookstone Capital Management purchased a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at about $42,000. Finally, Legacy Private Trust Co. bought a new stake in shares of Neumora Therapeutics during the 3rd quarter valued at about $25,000. Institutional investors own 47.65% of the company’s stock.

Trending Headlines about Neumora Therapeutics

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near-term EPS/2026 estimates and reduced projected losses for 2026–2028 (e.g., FY2026 now -$1.29 vs prior -$1.45; Q2/Q3/Q4 2026 trimmed). Improved near‑term visibility can be read as a bullish signal on operational progress. HC Wainwright estimate note
• Positive Sentiment: Brokerage support: Needham reiterated a Buy and Guggenheim issued a Buy; overall broker consensus is a “Moderate Buy” — these endorsements can support investor demand and liquidity. Needham reiterates Buy Guggenheim Buy Consensus Moderate Buy
• Positive Sentiment: Large call-option buying activity was reported, indicating speculative/bullish positioning by traders that can amplify near-term upside volatility. Options activity report
• Neutral Sentiment: Earnings call & roadmap coverage — company held its Q4 2025 call and management outlined upcoming catalysts (development milestones/pipeline priorities). These items set the event calendar but are mixed until concrete clinical or commercial results arrive. Q4 earnings call summary Catalyst roadmap
• Negative Sentiment: Shareholder litigation risk: The Schall Law Firm announced an investigation into possible false/misleading statements — this raises legal and disclosure risk and can pressure the stock while the probe runs. Schall Law Firm investigation
• Negative Sentiment: HC Wainwright cut longer‑term earnings projections (FY2029 and FY2030 lowered materially — FY2029 moved from +$0.07 to -$0.26; FY2030 from $2.02 to $1.51), which tempers the longer‑term upside narrative and could weigh on valuation multiples. HC Wainwright long-term revisions

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.